Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.

• DOI: 10.1200/jco.2014.32.15_suppl.7522
• Publication Date: 2019-01-03T22:35:36Z
• Authors: Zev A. Wainberg; Saeed Rafii; Ramesh K. Ramanathan; Lida A. Mina; Lauren Averett Byers; Rashmi Chugh; Jonathan Wade Gol...; Jasgit C. Sachdev; Daniela E. Matei; Jennifer J. Wheler; Joshua W. Henshaw; Charlie Zhang; Gilles Gallant; Johann Sebastian ...
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

7522 Background: BMN 673 is the most potent inhibitor of PARP1/2 in clinical development (IC50<1nM), inducing synthetic lethality in tumors deficient in homologous recombination. Based on preclinic...